Table 1.

The PD-1/PD-L1 inhibitors licensed for NSCLC treatment.

Checkpoint	Blocking agent	IgG isotype and characteristics	Clinical stage	Manufacturer
PD-1	Pembrolizumab	Humanized IgG4 mAb	EMA, FDA approved for first-line and second-line NSCLC treatment	Merck
	Nivolumab	Humanized IgG4 mAb	FDA approved for second-line NSCLC	Bristol-Myers Squibb
	Toripalimab	Humanized IgG4 mAb	Clinical trial ongoing	Shanghai Junshi
	Sintilimab	Fully human IgG4 mAb	Clinical trial ongoing	Innovent Biologics
	Camrelizumab	Humanized IgG4 mAb	Clinical trial ongoing	Hengrui Medicine
	Tislelizumab	Humanized IgG4 mAb	Clinical trial ongoing	BeiGene
	PDR001	Humanized IgG4 mAb	Clinical trial ongoing	Novartis
	REGN2810	Humanized IgG4 mAb	Clinical trial ongoing	Regeneron-Sanofi
PD-L1	Atezolizumab	High-affinity human IgG1	FDA approved for second-line NSCLC	Roche
	Durvalumab	Human IgG1 mAb	FDA approved for treatment of unresectable stage III NSCLC without relapse after chemoradiation	AstraZeneca
	BMS-936559	Fully high-affinity human IgG4	Clinical trial ongoing	Bristol-Myers Squibb

EMA, European Medicines Agency; FDA, US Food and Drug Administration; IgG, immunoglobulin G; mAb, monoclonal antibody; NSCLC, non-small-cell lung cancer; PD-1, programmed cell-death protein 1; PD-L1, programmed cell-death ligand 1.